spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  nimotuzumab 

 HSMN NewsFeed - 19 Oct 2018
Mylan and Biocon Announce Positive CHMP Opinion for Ogivri(R), Biosimilar Trastuzumab
Biopharmaceuticals Generics Oncology Regulatory
 HSMN NewsFeed - 14 Oct 2010
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 May 2008
Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Feb 2008
YM Biosciences USA Enrolls First Patient in Phase II Trial of Nimotuzumab in Children with Inoperable, Recurrent Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Aug 2007
YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Aug 2007
Oncoscience Ag, the European Partner of Ym Biosciences, Announces Completion of Patient Enrollment in Phase III Brain Cancer Trial of Nimotuzumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jun 2007
YM BioSciences Receives FDA Clearance for an IND for its Fentanyl-Based Pain Product AeroLEF(TM)
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 4 Jun 2007
YM BioSciences Cleared to Initiate Clinical trial of Nimotuzumab in Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Apr 2007
YM BioSciences' partner Daiichi Sankyo receives clearance for initial clinical trial in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Apr 2007
YM BioSciences Strengthens Program Management of Lead Drugs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Feb 2007
YM BioSiences Announces Management Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Jan 2007
YM BioSciences announces termination of the tesmilifene Phase III pivotal trial in advanced breast cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jul 2006
YM BioSciences reports anti-EGFr drug nimotuzumab approved in India for treatment of head and neck cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jun 2006
YM Biosciences announces independent Data Safety Monitoring Board recommends tesmilifene pivotal trial continue as planned
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2006
YM Biosciences completes acquisition of Eximias
Biopharmaceuticals Oncology Mergers & Acquisitions
Return to NewsFeed  

 Additional items found! 7

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 7 additional stories matching:
nimotuzumab
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.